2.1117

43.74% -1.7083

Pyxis Oncology Inc (PYXS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PYXS? Forum Prognose

Schlusskurs vom Vortag:

$3.82

Offen:

$2.17

24-Stunden-Volumen:

13.36M

Relative Volume:

17.14

Marktkapitalisierung:

$122.20M

Einnahmen:

Nettoeinkommen (Verlust:

$-73.79M

KGV:

-0.7436

EPS:

-2.84

Netto-Cashflow:

$-77.44M

1W Leistung:

-49.79%

1M Leistung:

-41.60%

6M Leistung:

-46.27%

1J Leistung:

+50.29%

1-Tages-Spanne:

$1.90

$2.39

1-Wochen-Bereich:

$1.90

$4.40

52-Wochen-Spanne:

$1.35

$6.85

Pyxis Oncology Inc Stock (PYXS) Company Profile

Firmenname

Pyxis Oncology Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

(617) 221-9059

Adresse

321 HARRISON AVENUE, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-11

Neueste SEC-Einreichungen

PYXS's Discussions on Twitter

Vergleichen Sie PYXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PYXS	2.125	122.20M	0	-73.79M	-77.44M	-2.84
VRTX	449.80	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.39	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	593.04	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	245.93	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.32	24.89B	3.30B	-501.07M	1.03B	11.54

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-11-02	Eingeleitet	BofA Securities	Neutral
2021-11-02	Eingeleitet	Credit Suisse	Outperform
2021-11-02	Eingeleitet	Jefferies	Buy

Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten

12:57 PM

Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn

12:57 PM

10:20 AM

Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha

10:20 AM

10:15 AM

Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn

10:15 AM

10:00 AM

Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn

10:00 AM

09:18 AM

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga

09:18 AM

08:38 AM

Pyxis Oncology (NASDAQ:PYXS) Downgraded to "Market Perform" Rating by William Blair - MarketBeat

08:38 AM

08:34 AM

HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat

08:34 AM

05:23 AM

Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St

05:23 AM

Nov 20, 2024

Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - Seeking Alpha

Nov 20, 2024

Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks

Nov 20, 2024

Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks

Nov 20, 2024

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times

Nov 20, 2024

Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com

Nov 20, 2024

Nov 18, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat

Nov 18, 2024

Nov 17, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat

Nov 17, 2024

Nov 15, 2024

Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat

Nov 15, 2024

FY2024 EPS Estimates for Pyxis Oncology Reduced by Analyst - MarketBeat

Nov 15, 2024

Nov 13, 2024

Laurion Capital Management LP Adjusts Stake in Pyxis Oncology Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024